WO1997008309A3 - Ribozyme therapy for hepatitis b infections - Google Patents
Ribozyme therapy for hepatitis b infections Download PDFInfo
- Publication number
- WO1997008309A3 WO1997008309A3 PCT/US1996/013975 US9613975W WO9708309A3 WO 1997008309 A3 WO1997008309 A3 WO 1997008309A3 US 9613975 W US9613975 W US 9613975W WO 9708309 A3 WO9708309 A3 WO 9708309A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hepatitis
- infections
- hbv
- infection
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52125595A | 1995-08-29 | 1995-08-29 | |
US08/521,255 | 1995-08-29 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1997008309A2 WO1997008309A2 (en) | 1997-03-06 |
WO1997008309A3 true WO1997008309A3 (en) | 1997-07-10 |
WO1997008309A9 WO1997008309A9 (en) | 1997-08-14 |
Family
ID=24076029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/013975 WO1997008309A2 (en) | 1995-08-29 | 1996-08-29 | Ribozyme therapy for hepatitis b infections |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1997008309A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0522578D0 (en) * | 2005-11-04 | 2005-12-14 | King S College London | Ribozymal nucleic acid |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0304578A1 (en) * | 1987-06-22 | 1989-03-01 | Medeva Holdings B.V. | Peptide comprising hepatitis B surface antigen |
WO1995022600A1 (en) * | 1994-02-22 | 1995-08-24 | Immusol, Inc. | Ribozyme therapy for hepatitis b infection |
-
1996
- 1996-08-29 WO PCT/US1996/013975 patent/WO1997008309A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0304578A1 (en) * | 1987-06-22 | 1989-03-01 | Medeva Holdings B.V. | Peptide comprising hepatitis B surface antigen |
WO1995022600A1 (en) * | 1994-02-22 | 1995-08-24 | Immusol, Inc. | Ribozyme therapy for hepatitis b infection |
Non-Patent Citations (5)
Title |
---|
BECK, J. AND NASSAL, M.: "Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells", NUCLEIC ACIDS RESEARCH, vol. 23, no. 24, 1995, pages 4954 - 4962, XP002029174 * |
GEORG, S.T. ET AL.: "Ribozyme-mediated cleavage of hepatitis B virus surface antigen mRNA", ANTIVIRAL RESEARCH, vol. 20, no. supp.1, 1993, pages 165, XP000652951 * |
KIJIMA, H. ET AL.: "Therapeutic applications of ribozymes", PHARMACEUTICAL THER., vol. 68, no. 2, 1995, pages 247 - 267, XP000612090 * |
WANG, P. ET AL.: "Effects of ribozyme on HBV in vitro and in HepG2 cell", FASEB JOURNAL, vol. 7, no. 7, 1993, pages a1301, XP002029175 * |
YU, M. ET AL.: "In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1", VIROLOGY, vol. 206, 1995, pages 381-386, XP000652043 * |
Also Published As
Publication number | Publication date |
---|---|
WO1997008309A2 (en) | 1997-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997032018A3 (en) | Hepatitis c virus ribozymes | |
WO2003044053A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
CA2210353A1 (en) | Stabilized external guide sequences | |
WO2003008443A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
HK1021648A1 (en) | Human plasma hyaluronidase | |
WO2004039829A3 (en) | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection | |
WO2002058638A3 (en) | Serpin drugs for treatment of hiv infection and method of use thereof | |
AU1664695A (en) | Process for producing endotoxin-free or endotoxin-poor nucleic acids and/or oligonucleotides for gene therapy | |
AU3698697A (en) | Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament | |
FR2711670B1 (en) | Nucleotide vector, composition containing it and vaccine for immunization against hepatitis. | |
MY113490A (en) | Modified anti-icam-1 antibodies and their use in the treatment of inflammation | |
AU4992985A (en) | Method and system for removing immunosuppressive components from the blood of mammals | |
BR9204699A (en) | COMPOUNDS CONTAINING IMIDAZOLINONE OR IMIDAZOLINTIONA GROUP, PROCESSES OF PREPARATIONS OF THESE COMPOUNDS, FUNGICIDED COMPOSITES AND CULTURE TREATMENT PROCESS | |
WO2002097030A3 (en) | Peptides derived from neural thread proteins and their medical use | |
WO2003039458A3 (en) | TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α | |
EP1857115A3 (en) | Using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells | |
WO1999063978A3 (en) | Methods of treating microbial infection and therapeutic formulations therefor | |
WO2002006513A3 (en) | A method for treating herpes viruses | |
CA2109977A1 (en) | Giardia vaccines | |
WO1997008309A3 (en) | Ribozyme therapy for hepatitis b infections | |
CA2138793A1 (en) | Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections | |
EP0552257A4 (en) | A plant protein useful for treating tumors and hiv infection | |
AU6111294A (en) | Composition for use in the treatment of tumours and the immunization of humans and animals | |
WO2002003061A3 (en) | Method for identifying substances which are suitable to be used for treating virus infections | |
EP1714979A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/6-6/6,DRAWINGS,REPLACED BY NEW PAGES 1/8-8/8;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |